Kelun-Biotech (002422.SZ) subsidiary presents multiple innovative drug research results at the 2026 ESMO Congress

Zhitong Finance APP news, Kelun Pharmaceutical (002422.SZ) announced that the company recently learned that its controlled subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as "Kelun-Biotech") presented multiple clinical research results at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, from October 23 to 27, covering relevant data on the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) () and the B7-H3-targeting ADC SKB500.